Claims

What is claimed is:

1. A compound having the formula:

N N R

wherein,

5

10

15

20

25

Each R¹ and R² is independently R³; R⁸; NHR³; NHR⁵; NHR⁶; NR⁵R⁵; NR⁵R⁶; SR⁵; SR⁶; SR³; OR⁵; OR⁵, OR³; C(O)R³; heterocyclyl optionally substituted with 1-4 independent R⁴ on each ring; or C1-C10 alkyl substituted with 1-4 independent R⁴;

Each R^3 is independently aryl; phenyl optionally substituted with 1-5 independent R^4 on each ring; or heteroaryl optionally substituted with 1-4 independent R^4 on each ring;

Each n is independently 1 or 2;

Each m is independently 0, 1, 2, 3, or 4;

Each R⁵ is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R⁹; haloalkyl, C1-C10 alkyl substituted with 1-3 independent aryl, R⁷ or R⁹ groups; C3-C10 cycloalkyl substituted

15

20

25

30

with 1-3 independent aryl, R⁷ or R⁹ groups; or C2-C10 alkenyl substituted with 1-3 independent aryl, R⁷ or R⁹;

Each R⁶ is independently C(O)R⁵, COOR⁵, C(O)NR⁵R⁵, C(N R⁵) NR⁵R⁵,

 $S(O)_n R^5$; Each R^7 is independently halo, CF_3 , SR^{10} , OR^{10} , $OC(O)R^{10}$, $NR^{10}R^{10}$, $NR^{10}R^{11}$, $NR^{11}R^{11}$, $COOR^{10}$, NO_2 , CN, $C(O)R^{10}$, $OC(O)NR^{10}R^{10}$, $C(O)NR^{10}R^{10}$, $N(R^{10})C(O)R^{10}$, $N(R^{10})$ (COOR¹⁰), $S(O)_{n}NR^{10}R^{10}$; $NR^{10}S(O)_{n}NR^{10}R^{10}$; $NR^{10}S(O)_{n}R^{10}$; or $P(O)(OR^5)_2$;

Each R⁸ is independently a 3-8 membered monocyclic, 7-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms independently selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2, 3 or 4 atoms of each ring may be substituted by a substituent independently selected from C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R⁹; halo; sulfur; oxygen; CF₃; SR⁵; OR⁵; $OC(O)R^5$; NR^5R^5 ; NR^5R^6 ; NR^6R^6 ; $COOR^5$; NO_2 ; CN; $C(O)R^5$; $C(O)NR^5R^5$; $S(O)_{n}NR^{5}R^{5}$; $NR^{5}C(O)NR^{5}R^{5}$; $NR^{5}C(O)R^{9}$; $NR^{5}S(O)_{n}NR^{5}R^{5}$; $NR^{5}S(O)_{n}R^{9}$; C1-C10alkyl substituted with 1-3 independent R⁷, R⁹ or aryl; or C2-C10 alkenyl substituted with 1-3 independent R⁷, R⁹ or arvl:

Each R⁹ is independently a 3-8 membered monocyclic, 7-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms independently selected from O, N, or S, which may be saturated or unsaturated, and wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a\substituent independently selected from C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; halo; sulfur; oxygen; CF₃; haloalkyl; SR¹⁰; OR¹⁰; NR¹⁰R¹⁰; NR¹⁰R¹¹; $NR^{11}R^{11};COOR^{10};NO_2;CN;C(O)R^{10};S(O)_nR^{10};S(O)_nNR^{10}R^{10};or^{\dagger}C(O)NR^{10}R^{10};$

Each R¹⁰ is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; haloalkyl; C1-C10 alkyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3a' Conts

10

15

20

25

C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF₃, OR¹², SR¹², NR¹²R¹², COOR¹², NO₂, CN, C(O)R¹², C(O)NR¹²R¹², NR¹²C(O)R¹², N(R¹²)(COOR¹²), S(O)_nNR¹²R¹², or OC(O)R¹²; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF₃, OR¹², SR¹², NR¹²R¹², COOR¹², NO₂, CN, C(O)R¹², C(O)NR¹²R¹², NR¹²C(O)R¹², N(R¹²)(COOR¹²), S(O)_nNR¹²R¹², or OC(O)R¹²;

Each R^{11} is independently $C(O)R^{10}$, $COOR^{10}$, $C(O)NR^{10}R^{10}$ or $S(O)_nR^{10}$;

Each R¹² is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; C1-C10 alkyl substituted with 1-3 independent C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF₃, OR¹³, SR¹³, NR¹³R¹³, COOR¹³, NO₂, CN, C(O)R¹³, C(O)NR¹³R¹³, NR¹³C(O)R¹³, or OC(O)R¹³; or phenyl optionally substituted with 1-3 independent C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C4-C10 cycloalkenyl, halo, CF₃, OR¹³, SR¹³, NR¹³R¹³, COOR¹³, NO₂, CN, C(O)R¹³, C(O)NR¹³R¹³, NR¹³C(O)R¹³, or OC(O)R¹³;

Each R¹³ is independently H; C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; C1-C10 alkyl optionally substituted with halo, CF₃, OR¹⁴, SR¹⁴, NR¹⁴R¹⁴, COOR¹⁴, NO₂, CN; or phenyl optionally substituted with halo, CF₃, OR¹⁴, SR¹⁴, NR¹⁴R¹⁴, COOR¹⁴, NO₂, CN;

Each R¹⁴ is independently H; C1-C10 alkyl; C3-C10 cycloalkyl or phenyl;

Each R¹⁵ is independently H; CF₃; CN; COOR⁵; or C1-C10 alkyl substituted with 1-3 independent OR⁵, SR⁵, or NR⁵R⁵;

Each R¹⁶ is independently H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R⁸; halo; haloalkyl; CF₃; COOR⁵; C(O)R⁵; C(O)C(O)R⁵; C(O)NR⁵R⁵; S(O)_nR^{5:} S(O)_nNR⁵R⁵; C1-C10 alkyl substituted with 1-3 independent aryl, R⁷, R⁸, or phenyl optionally substituted with substituted with 1-4 independent R²³; or C2-C10 alkenyl substituted with 1-3 independent aryl, R⁷ or R⁸;

Each R¹⁷ is independently NR⁵R¹⁶; OR⁵; SR⁵; or halo;

20

25

Each R^{18} is independently C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R^8 ; halo; haloalkyl; CF₃; COOR⁵; C(O)C(O)R⁵; C(O)NR⁵R⁵; S(O)_nR⁵: S(O)_nNR⁵R⁵; C1-C10 alkyl substituted with 1-3 independent aryl, R^7 or R^8 ; or C2-C10 alkenyl substituted with 1-3 independent aryl, R^7 or R^8 ;

Each R¹⁹ is independently H or C1-C6 alkyl;

Each R²⁰ is independently NR⁵R¹⁸; OR⁵; SR⁵; or halo;

Each R²¹ is independently t-butyl, 4-carboxyphenyl, 4-carboxyphenyl, or faryl substituted with 1-4 independent R⁴;

Each R²² is independently C2-C9 alkyl substituted with 1-2 independent aryl, R⁷, or R⁸;

Each R^{23} is independently selected from H, C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R^8 ; halo; haloalkyl; CF3; SR⁵; OR⁵; OC(O)R⁵; NR⁵R⁵; NR⁵R⁶; COOR⁵; NO2; CN; C(O)R⁵; C(O)C(O)R⁵; S(O)_nR⁵: S(O)_nNR⁵R⁵; NR⁵C(O)NR⁵R⁵; NR⁵C(O)C(O)R⁵; NR⁵C(O)C(O)R⁸; NR⁵C(O)R⁸; NR⁵S(O)_nR⁸; NR⁵S(O)_nR⁸; NR⁵C(O)C(O)NR⁵R⁵; NR⁵C(O)C(O)NR⁵R⁵; OC(O)NR⁵R⁵; OS(O)_nNR⁵R⁵; NR⁵S(O)_nOR⁵; OS(O)_nNR⁵R⁵; NR⁵S(O)_nOR⁵; P(O)(OR⁵)₂; C1-C10 alkyl substituted with 1-3 independent aryl, R⁷ or R⁸; or C2-C10 alkenyl substituted with 1-3 independent aryl, R⁷ or R⁸;

Each R²⁴ is independently selected from C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; aryl; R⁹; halo; sulfur; oxygen; CF₃; SR⁵; OR⁵; OC(O)R⁵; NR⁵R⁵; NR⁵R⁶; NR⁶R⁶; COOR⁵; NO₂; CN; C(O)R⁵; C(O)NR⁵R⁵; S(O)_nNR⁵R⁵; NR⁵C(O)NR⁵R⁵; NR⁵C(O)R⁵; NR⁵S(O)_nNR⁵R⁵; NR⁵S(O)_nR⁹; C1-C10 alkyl substituted with 1-3 independent R⁷, R⁹ or aryl; or C2-C10 alkenyl substituted with 1-3 independent R⁷, R⁹ or aryl;

Each X is independently O or S;

Each V, W, Y, and Z is independently N or CR⁴;

Each haloalkyl is independently a C1-C10 alkyl substituted with one or more halogen atoms, selected from F, Cl, Br, or I, wherein the number of halogen atoms may not exceed that number that results in a perhaloalkyl group;

a' cont

10

15

20

25

30

Each aryl is independently a 6-carbon monocyclic, 10-carbon bicyclic or 14-carbon tricyclic aromatic ring system optionally substituted with 1-3 independent C1-C10 alkyl; C2-C10 alkenyl; C2-C10 alkynyl; C3-C10 cycloalkyl; C4-C10 cycloalkenyl; R9; halo; haloalkyl; CF3; OR¹⁰; SR¹⁰; NR¹⁰R¹⁰; NR¹⁰R¹¹; COOR¹⁰; NO₂; CN; C(O)R¹⁰; C(O)C(O)R¹⁰; C(O)NR¹⁰R¹⁰; N(R¹⁰)C(O)NR¹⁰R¹⁰; N(R¹⁰)C(O)R¹⁰; N(R¹⁰)S(O)_nR¹⁰; N(R¹⁰)S(O)_nR¹⁰; N(R¹⁰)C(O)C(O)R¹⁰; NR¹⁰C(O)C(O)R⁹; NR¹⁰S(O)_nNR¹⁰R¹⁰; NR¹⁰S(O)_nR⁹; NR¹²C(O)C(O)NR¹²R¹²; S(O)_nR¹⁰; S(O)_nNR¹⁰R¹⁰; OC(O)R¹⁰; C1-C10 alkyl substituted with 1-3 independent R9, halo, CF3, OR¹⁰, SR¹⁰, OC(O)R¹⁰, NR¹¹R¹¹, NR¹⁰R¹⁰, N(R¹⁰), COOR¹⁰, NO₂, CN, C(O)R¹⁰, OC(O)NR¹⁰R¹⁰, C(O)NR¹⁰R¹⁰, N(R¹⁰)C(O)R¹⁰, N(R¹⁰) (COOR¹⁰), S(O)_nNR¹⁰R¹⁰; R¹⁰; or C2-C10 alkenyl substituted with 1-3 independent R9, halo, CF3, OR¹⁰, SR¹⁰, OC(O)R¹⁰, NR¹¹R¹¹, NR¹⁰R¹¹, COOR¹⁰, NO₂, CN, C(O)R¹⁰, OC(O)NR¹⁰R¹⁰, N(R¹⁰)C(O)R¹⁰, N(R¹⁰)

Each heterocyclyl is independently a 3-8 membered nonaromatic monocyclic, 8-12 membered nonaromatic bicyclic, or 11-14 membered nonaromatic tricyclic, ring system comprising 1-4 heteroatoms if monocyclic, 1-8 heteroatoms if bicyclic, or 1-10 heteroatoms if tricyclic, said heteroatoms independently selected from O, N, or S; and

Each heteroaryl is independently a 5-8 membered aromatic monocyclic, 8-12 membered aromatic bicyclic, or 11-14 membered aromatic tricyclic ring system comprising 1-4 heteroatoms if monocyclic, 1-8 heteroatoms if bicyclic, or 1-10 heteroatoms if tricyclic, said heteroatoms independently selected from O, N, or S.

2. The compound of claim 1 wherein, R^1 is independently R^3 ; and R^2 is independently NHR³.

3. The compound of claim 1 wherein,

R¹ is independently heteroaryl optionally substituted with 1-4 independent on each ring; and R² is independently NHR³. a' 4. The compound of claim 1 wherein, is independently phenyl optionally substituted with 1-5 independent R⁴; and R² is independently NHR³. 10 5. The compound of claim 1 wherein, Each R^1 and R^2 is independently NHR³. 15 6. The compound of claim 1 wherein, R¹ is independently NHR⁵; and R² is independently NHR³ 20 7. The compound of claim 1 wherein, R¹ is independently NHR⁶; and R² is independently NHR³. 8. The compound of claim 1 wherein, 25 R¹ is independently OR⁵; and R² is independently NHR³. 9. The compound of claim 1 wherein, R¹ is independently SR⁵; and 30 R² is independently NHR³.

10

15

20

25

10. The compound of claim 1 wherein:

 R^2 is independently NHR³; and

 \mathbb{R}^1 is one of the following groups:

$$R^4$$

$$R^4$$

$$R^4$$

$$R^4$$

$$R^4$$

$$R^4$$

11. The compound of claim 1 wherein,

 R^1 is independently heterocyclyl optionally substituted with 1-4 independent R^4 on each ring, wherein said heterocyclyl is not unsubstituted piperidine; and

R² is independently NHR³.

12. The compound of claim 1 wherein,

Each R¹ is independently heteroaryl substituted with 1- 4 independent R⁴ on each ring, wherein said heteroaryl comprises at least one mirrogen heteroatom and said heteroaryl is attached at said nitrogen heteroatom; and

Each R² is independently NHR³.

13. The compound of claim 1 wherein,

Each R¹ is independently heterocyclyl substituted with 1-4 independent R⁴ on each ring, wherein said heterocyclyl is not unsubstituted piperidine, and said

15

heterocyclyl comprises at least one nitrogen heteroatom and said heterocyclyl is attached at said nitrogen heteroatom; and

Each R² is independently NHR³.

14. The compound of claim 1 wherein,

Each R² is independently NHR³; and

Each \mathbb{R}^1 is independently of the formula:

$$R^4$$
 R^4
 R^4
 R^4

15. The compound of claim 1 wherein,

Each R² is independently NHR³; and

Each R¹ is independently of the formula:

$$R^4$$
 R^4
 R^4
 R^4

16. The compound of claim 1 wherein,

Each R² is independently NHR³; and Each R¹ is independently of the formula:

a/ Cont


R⁴ R⁴

5

17. The compound of claim 1 wherein

Each R² is independently NHR³, and

Each R¹ is independently of the formula:



10

18. The compound of claim 1 wherein,

Each R¹ is independently one of the following groups:

15

10

Wherein m is 0, 1, 2, 3 or A

19. The compound of claim wherein,

Each R¹ is independently

20. The compound of claim 1 wherein,

10

Confidential Confidential St. Confidential C

or halo



wherein the groups are as defined in claim 1.

Cont

21. The compound of claim 1 wherein,

Each R¹ is independently

wherein R 10 is independently H or C1-C6 alkyl.

- 22. A composition comprising a compound of any of claims 1-21 and a pharmaceutically acceptable carrier.
- 23. The composition of claim 22, further comprising at least one additional therapeutic agent.

15

10

24. A method of treating kinase-mediated disease or disease symptoms in a mammal comprising administration of a composition comprising a compound of any of claims 1-21.

20

- 25. A method of inhibiting kinase activity in a mammal comprising administration of a composition comprising a compound of any of claims 1-21.
- 26. A method of treating disease or disease symptoms in a mammal comprising administration of a composition comprising a compound of any of claims 1-21.



27. A method of inhibiting angiogenesis or vasculogenesis activity in a mammal comprising administration of a composition comprising a compound of any of claims 1-21.

Cont

- 28. A method of making a pharmaceutically useful composition comprising combining a compound of any of claims 1-21 with one or more pharmaceutically acceptable carriers.
- 29. The method of claim 28, further comprising combining an additional therapeutic agent.
 - 30. A method of making a compound of claim 1 of the formula

$$R^2$$
 N R^1


wherein

15

20

Each R¹ and R² is independently R³; R⁸; NHR³; NHR⁵; NHR⁶; NR⁵R⁵; NR⁵R⁶; SR⁵; SR⁶; SR³; OR⁵; OR⁶; OR³; C(O)R³; heterocyclyl optionally substituted with 1-4 independent R⁴ on each ring; or C1-C10 alkyl substituted with 1-4 independent R⁴;


Each R^3 is independently aryl; phenyl optionally substituted with 1-5 independent R^4 on each ring; or heteroaryl optionally substituted with 1-4 independent R^4 on each ring; comprising the steps of:



a) reacting a compound of formula (II) wherein each L is independently a leaving group as defined herein, with a nucleophile of formula H-R¹ (or salt thereof) to give a compound of formula (III); and



- b) reacting the compound of formula (III) with a nucleophile of formula H-R² (or salt thereof) to give a compound of formula (I).
- 31. A method of making a compound of claim 1 comprising reacting a triazine of one or more of the formulae:



$$R^2$$

with an appropriate nucleophilic agent or agents, wherein L is a leaving group and the other groups in said formulae are as defined in claim 1.



15

10

add Bi